◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Direxion Daily Biotech Top 5 Bull 2X ETF (TBXU) ETF Overview

Name: Direxion Daily Biotech Top 5 Bull 2X ETF (TBXU) price history and fund statistics
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Price history, fund statistics and profile — an exchange-traded fund.

Exchange-Traded Funds · Trading--Leveraged Equity · DATA UPDATED 2026-08-31

Direxion Daily Biotech Top 5 Bull 2X ETF (TBXU) is an exchange-traded fund managed by Direxion Funds in the "Trading--Leveraged Equity" category. It manages roughly $3 million in assets.

The fund, under normal circumstances, invests at least 80% of its net assets (plus borrowing for investment purposes) in financial instruments, such as swap agreements, securities of the index, and exchange-traded funds ("ETFs") that track the index, that, in combination, provide 2X daily leveraged exposure to the index, consistent with the fund's investment objective.

Interactive chart & fund stats →

TBXU Fund Statistics

Expense ratio	0.98%
Assets under management	$3 million
Fund category	Trading--Leveraged Equity
Fund family	Direxion Funds
Inception	2025-09-30

The live price chart, fund profile and news are in the interactive TBXU viewer.

Other Companies in Trading--Leveraged Equity

CATG · Leverage Shares 2X Long CAT Daily ETF — $3 million
LITU · T-Rex 2X Long Lite Daily Target ETF — $3 million
EUVX · Corgi Lithography & Semiconductor Photonics 2x Daily ETF — $3 million
BIDG · Leverage Shares 2X Long BIDU Daily ETF — $3 million
OKTG · Leverage Shares 2X Long OKTA Daily ETF — $3 million
GLGG · Leverage Shares 2X Long GLXY Daily ETF — $3 million
MPWX · Tradr 2X Long MPWR Daily ETF — $2 million
SNAG · Leverage Shares 2X Long SNAP Daily ETF — $2 million

← TBX All “T” companies TC →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.